CN Mobile Logo

Search form


ASCO 2016

2016 ASCO Annual Meeting

Cancer Network presents exclusive coverage of the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Check out some of our topic specific ASCO coverage:

Breast Cancer | Gynecologic Cancers | Hematologic Malignancies | Lung Cancer | Prostate Cancer | Sarcoma

ASCO 2016

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.

The MEK inhibitor binimetinib resulted in improved progression-free survival and response rates vs dacarbazine in patients with NRAS-mutated metastatic melanoma.

Long-term follow-up of a phase I and a phase II study shows that nivolumab produces strong overall survival benefit in patients with advanced renal cell carcinoma.

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

Cabozantinib significantly improved the overall survival of patients with previously treated advanced RCC, according to the second interim analysis of the METEOR trial.


Subscribe to ASCO 2016 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.